ReviewPatient preference and adherence2021
Improving Adherence to Topical Medication in Patients with Glaucoma.
Review in Patient preference and adherence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07690397 (GLAUCO-TECH Study), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GLAUCO-TECH Study: Safety & Efficacy of Preservative-free vs. Preserved Dorzolamide-Timolol-Brimonidine. Impact on the Ocular Surface, Glaucoma Progression, Tear Proteomics, and AI/Chatbot-led Patient Follow-up.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.BMC ophthalmology · 2026Pooled it
- Interventions for improving adherence to amblyopia treatments in children.The Cochrane database of systematic reviews · 2025Pooled it
- Multifaceted behavioral interventions to improve topical glaucoma therapy adherence in adults.The Cochrane database of systematic reviews · 2025Pooled it
- Real-World Transition to a Preservative-Free Fixed Combination of Dorzolamide/Timolol: Impact on the Ocular Surface Microenvironment, Safety, Tolerability, and Efficacy.Medicina (Kaunas, Lithuania) · 2026Trial
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.Scientific reports · 2023Trial
- Use of Bimatoprost Intracameral Implant for the Treatment of Glaucoma: A Focused Narrative Review.Cureus · 2026Review
- A Comprehensive Approach to Days' Supply Estimation in a Real-World Prescription Database: Algorithm Development and Validation Study.Online journal of public health informatics · 2026Article
- Micropulse Laser Trabeculoplasty in Glaucoma: Efficacy and Safety in a Clinical Cohort.Medicina (Kaunas, Lithuania) · 2025Article
- Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society.Advances in therapy · 2025Article
- Efficacy of Canaloplasty for the Management of Primary Open-Angle Glaucoma: Protocol for a Systematic Review.JMIR research protocols · 2025Article
- Epinastine Eyelid Cream as a Practical Option for Patients With Glaucoma on Multidrug Topical Therapy: A Case Report.Cureus · 2025Article
- Comparison of Efficacy and Ocular Surface Assessment Between Preserved and Preservative-Free Brimonidine/Timolol Fixed-Combination Eye Drops in Glaucoma Patients: A Parallel-Grouped, Randomized Trial.Journal of clinical medicine · 2025Article
- Article
- Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma.Ophthalmology and therapy · 2024Article
- Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension.Ophthalmology and therapy · 2024Article
- Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.Current allergy and asthma reports · 2024Review
- Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.Korean journal of ophthalmology : KJO · 2024Article
- Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Evidence in Practice: A Review of Real-Life Studies and Clinical Experience with the Preservative-Free Tafluprost (0.0015%) and Timolol (0.5%) Fixed-Dose Combination.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glaucomas form a heterogenous group of conditions, which collectively account for one of the most common irreversible causes of blindness worldwide. The only treatment, for which there is evidence, to stop or slow glaucomatous disease progression is to lower intraocular pressure (IOP); this is most often initially achieved with topical medication. Adherence to anti-glaucoma therapy is known to be low even when compared with adherence to therapy for other chronic conditions. We performed a PubMed search to review evidence as to how adherence to and persistence with anti-glaucoma medications might be improved. Approaches to improving adherence include technological (such as using smart drop bottles or automated reminders) use of instillation aids, improving communication with patient education and improving tolerability of eye drop formulations. There is limited short-term evidence that automated reminders can be effective and, unfortunately, instillation aids have not proved to be efficacious with respect to improving adherence. A range of factors have been identified which affect adherence and persistence, although only a multi-faceted approach has proven evidence of efficacy, compared to improved patient education alone. There is now a wider range of available preservative-free eye drops, which have been shown to be non-inferior in achieving IOP control, with fewer side effects and improved short-term adherence. Further studies relating to adherence are warranted, particularly given the projected increase in glaucoma prevalence worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.